• Castillo RodriguezBeatrizBDivision of Internal Medicine, Baylor College of Medicine, Houston, Texas., Eric A Secemsky, Rajesh V Swaminathan, Dmitriy N Feldman, Markus Schlaich, Yuri Battaglia, Edward J Filippone, and Chayakrit Krittanawong.
• Division of Internal Medicine, Baylor College of Medicine, Houston, Texas.
• Am. J. Med. 2024 Aug 1; 137 (8): 712718712-718.

AbstractHypertension is a primary contributor to cardiovascular disease, and the leading risk factor for loss of quality adjusted life years. Up to 50% of the cases of hypertension in the United States remain uncontrolled. Additionally, 8%-18% of the hypertensive population have resistant hypertension; uncontrolled pressure despite 3 different antihypertensive agents. Recently, catheter-based percutaneous renal denervation emerged as a method for ablating renal sympathetic nerves for difficult-to-control hypertension. Initial randomized (non-sham) trials and registry analyses showed impressive benefit, but the first sham-controlled randomized controlled trial using monopolar radiofrequency ablation showed limited benefit. With refinement of techniques to include multipolar radiofrequency, ultrasound denervation, and direct ethanol injection, randomized controlled trials demonstrated significant blood pressure improvement, leading to US Food and Drug Administration approval of radiofrequency- and ultrasound-based denervation technologies. In this review article, we summarize the major randomized sham-controlled trials and societal guidelines regarding the efficacy and safety of renal artery denervation for the treatment of uncontrolled hypertension.Copyright © 2024 Elsevier Inc. All rights reserved.

14 keywords...

hide…